罕见的15号外显子BRAF突变甲状腺乳头状癌呈惰性行为:单中心经验
该单中心研究于2006至2013年收集2961例甲状腺乳头状癌(PTC),筛查15号外显子BRAF变异。1186例(40.0%)存在该变异,其中V600E占95.3%(1131/1186),罕见变异(r-BRAF)占4.7%(55/1186)。r-BRAF多见于微小癌和滤泡变异型,绝大多数为单灶、完全包膜内、甲状腺内病变,淋巴结转移率低(1/55,1.8%),诊断时分期较早(I/II期51/55,92.7%)。
要点
- r-BRAF在PTC中非常罕见,占所有15号外显子BRAF变异的4.7%(55/1186)。
- r-BRAF最常见为BRAF K601E(35/55,63.6%)。
- r-BRAF肿瘤多呈低危临床病理特征:单灶61.8%、完全包膜83.6%、甲状腺内96.4%。
核心结论
- r-BRAF在PTC中非常罕见,几乎仅见于具有低危临床病理特征的PTC。
研究设计与样本
- 单中心研究,2006至2013年共收集2961例PTC,筛查15号外显子BRAF变异。
主要发现
- 2961例PTC中1186例(40.0%)存在15号外显子BRAF变异,其中V600E 1131/1186(95.3%),r-BRAF 55/1186(4.7%)。
- r-BRAF见于18例微小癌、33例滤泡变异型、1例经典型和1例梁状/实性变异型。
- r-BRAF最常见为BRAF K601E(35/55,63.6%),其次为BRAF V600_K601delinsE(7/55,12.7%)和BRAF T599I-V600_R603del(2/55,3.6%),其余11种变异各仅见1例。
- r-BRAF肿瘤大多为单灶(34/55,61.8%)、完全包膜(46/55,83.6%)、甲状腺内(53/55,96.4%),淋巴结转移率低(1/55,1.8%),诊断时分期较早(美国癌症联合委员会I/II期51/55,92.7%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Approximately 40% of papillary thyroid carcinomas (PTCs) harbor the BRAF V600E mutation, which is significantly associated with the advanced clinicopathological features of PTC at diagnosis, a higher recurrence rate, and disease-related mortality. BRAF alterations other than V600E are less common in PTC, and their clinical significance remains to be established. OBJECTIVE: The aim of the study was to describe a large cohort of rare exon 15 BRAF alterations (r-BRAF) and the clinicopathological features of PTC harboring these alterations and to clarify their clinical significance. METHODS: A total of 2961 PTCs were collected from 2006 to 2013 and screened for exon 15 BRAF alterations. RESULTS: Exon 15 BRAF alterations were found in 1186 of 2961 PTC cases (40.0%). In particular, we found the BRAF V600E mutation in 95.3% (1131 of 1186) and r-BRAF in 4.7% (55 of 1186) of the cases. r-BRAF were found in 18 microcarcinomas, 33 follicular variants, one classic variant, and one trabecular/solid variant. The most frequent r-BRAF was BRAF K601E (35 of 55; 63.6%), followed by BRAF V600_K601delinsE (seven of 55; 12.7%) and BRAF T599I-V600_R603del (two of 55; 3.6%). The remaining 11 alterations were found in one case only. The large majority of these tumors were unifocal (34 of 55; 61.8%), completely encapsulated (46 of 55; 83.6%), and intrathyroidal (53 of 55; 96.4%) with a low prevalence of lymph node metastases (one of 55; 1.8%) and a less advanced tumor stage at diagnosis (American Joint Commission on Cancer stage I/II, 51 of 55; 92.7%). CONCLUSIONS: r-BRAF are very uncommon in PTC and are found almost exclusively in PTC with low-risk clinicopathological features.
引用
- Torregrossa L, Viola D, Sensi E, et al. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. J Clin Endocrinol Metab. 2016. PMID: 27571181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。